DYSPORT for Injection AbobotulinumtoxinA Neurotoxin Clinical and Health Economics Outcomes Registry in Cervical Dystonia (ANCHOR-CD).

Trial Profile

DYSPORT for Injection AbobotulinumtoxinA Neurotoxin Clinical and Health Economics Outcomes Registry in Cervical Dystonia (ANCHOR-CD).

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Torticollis
  • Focus Therapeutic Use
  • Acronyms ANCHOR-CD
  • Sponsors Ipsen
  • Most Recent Events

    • 08 Jun 2017 Results (n=843) evaluating impact of injection interval on patient satisfaction using patient data from INTEREST IN CD2 & ANCHOR-CD trials, presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
    • 15 Sep 2016 Data from this trial has been selected for presentation at the annual meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), as reported by Ipsen Biopharmaceuticals media release.
    • 21 Apr 2016 Results (n=350) of abobotulinumtoxinA injection usage patterns in patients were presented at the 68th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top